Shield shares jump after FDA extends Accrufer exclusivity Proactive uses images sourced from Shutterstock Broker Cavendish says additional US protection strengthens long-term outlook and reiterates buy rating. Shares in Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) jumped as much 11% earlier in the session after the company said US regulators had granted an additional three years of data exclusivity for its oral iron therapy Accrufer. The AIM-listed pharmaceuticals group said the US Food and Drug Admin ...